证券代码：000504 证券简称：南华生物 公告编号：2025-022 南华生物医药股份有限公司 关于召开 2024 年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、召开会议的基本情况 1.股东大会届次：公司2024年度股东大会。 2.股东大会的召集人：公司董事会。 经南华生物医药股份有限公司（以下简称"公司"）第十一届董事会第二十 六次会议审议，决定召开2024年度股东大会。 3.会议召开的合法、合规性： 本次股东大会会议召开符合《中华人民共和国公司法》《中华人民共和国证 券法》《上市公司股东大会规则》等法律、行政法规、部门规章、规范性文件和 《公司章程》的规定。 4.会议召开的日期、时间： 1）现场会议召开时间：2025 年 5 月 22 日下午 15:00； 2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为2025 年5月22日，9:15-9:25，9:30-11:30，13:00-15:00；通过互联网投票系统进行 网络投票的时间为2025年5月22日9:15-15:00。 5.会议的召开方式：本次股东大会采用 ...

证券代码：000504 证券简称：南华生物 公告编号：2025-016 南华生物医药股份有限公司 第十一届监事会第十八次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、监事会会议召开情况 南华生物医药股份有限公司（以下简称"公司"）第十一届监事会第十八次 会议于2025年4月28日以通讯方式召开。会议通知于2025年4月18日以邮件、短信 方式送达公司全体监事。会议应参与表决监事3名，实际参与表决监事3名。会议 召开符合《公司法》及《公司章程》的有关规定，合法有效。 二、监事会议案审议情况 1.《关于<2024年度监事会工作报告>的议案》 表决结果：会议以3票赞成，0票反对，0票弃权，审议并通过了《关于<2024 年度监事会工作报告>的议案》。 本议案尚需提交2024年年度股东大会审议，具体内容详见公司于同日披露于 指定媒体的《2024年度监事会工作报告》。 同意将公司2024年财务决算报告提交2024年度股东大会审议。 表决结果：会议以3票赞成，0票反对，0票弃权，审议并通过了《关于<2024 年财务决算报告>的议案》。 具体内容详见公司 ...

证券代码：000504 证券简称：南华生物 公告编号：2025-015 第十一届董事会第二十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 南华生物医药股份有限公司（以下简称"公司"）第十一届董事会第二十六 次会议于2025年4月28日以通讯方式召开。会议通知于2025年4月18日以邮件、短 信方式送达公司全体董事。会议应参与表决董事7名，实际参与表决董事7名。会 议召开符合《公司法》及《公司章程》等的有关规定，合法有效。 二、董事会议案审议情况 1.《关于<2024年度董事会工作报告>的议案》 南华生物医药股份有限公司 表决结果：会议以7票赞成，0票反对，0票弃权，审议并通过了《关于<2024 年度董事会工作报告>的议案》。 独立董事向董事会递交了2024年度述职报告及独立性自查报告，并将在公司 2024年度股东大会上述职。 本议案尚须提交公司股东大会审议，具体内容详见同日披露于指定媒体的 《2024年度董事会工作报告》。 2.《关于<2024年度总经理工作报告>的议案》 表决结果：会议以7票赞成，0票反对，0票弃 ...

证券代码：000504 证券简称：南华生物 公告编号：2025-018 南华生物医药股份有限公司 关于 2024 年度拟不进行利润分配的公告 | 回购注销总额 | 0 | 0 | 0 | | --- | --- | --- | --- | | （万元） | | | | | 归属于上市公司股 | | | | | 东的净利润 | -1,984.60 | -2,817.26 | -1,245.74 | | （万元） | | | | | 合并报表本年度末 | | | | | 累计未分配利润 | | -55,094.65 | | | （万元） | | | | | 母公司报表本年度 | | | | | 末累计未分配利润 | | -39,258.48 | | | （万元） | | | | | 上市是否满三个完 | | 是 | | | 整会计年度 | | | | | 最近三个会计年度 | | | | | 累计现金分红总额 | | 0 | | | （万元） | | | | | 最近三个会计年度 | | | | | 累计回购注销总额 | | 0 | | | （元） | | | | | 最近三个会计年度 | | | | | 平均净 ...

证券代码：000504 证券简称：南华生物 公告编号：2025-024 南华生物医药股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、股票交易异常波动的情况介绍 南华生物医药股份有限公司（以下简称"公司"或"南华生物"）股票（证 券简称：南华生物，证券代码：000504）于2025年4月24日、2025年4月25日、2025 年4月28日连续三个交易日内收盘价格跌幅偏离值累计超过20%，根据《深圳证券 交易所交易规则》的有关规定，属于股票异常波动情形。 二、公司关注并核实情况 （一）公司核查情况 针对公司股票交易异常波动，公司对有关事项进行了核查，对影响公司股票 异常波动的情况说明如下： 1.公司于2025年4月22日对2024年年度业绩预告进行了修正，具体内容详见 《关于2024年年度业绩预告修正暨可能被实施退市风险警示的公告》（公告编号： 2025-011）。除此之外，公司前期披露的信息不存在需要更正、补充之处； 2.近期公共传媒未出现报道了可能或已经对本公司股票交易价格产生较大 影响的未公开重大信息； 3.近期公司 ...

证券代码：000504 证券简称：南华生物 公告编号：2025-023 南华生物医药股份有限公司 关于公司股票交易被实施退市风险警示暨停牌的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 特别提示： 根据天健会计师事务所（特殊普通合伙）出具的《南华生物2024年度审计报 告》，公司2024年度利润总额、净利润、扣除非经常性损益后的净利润均为负值 且扣除后营业收入低于3亿元。根据《深圳证券交易所股票上市规则》有关规定， 上市公司出现"最近一个会计年度经审计的利润总额、净利润、扣除非经常性损 益后的净利润三者孰低为负值，且扣除后的营业收入低于3亿元"的情形，公司 股票交易将被实施退市风险警示。 经公司自查，除上述被实施退市风险警示的情形外，公司不存在其他需被实 施退市风险警示和其他风险警示的情形。 二、股票种类、股票简称、股票代码、实施退市风险警示的起始日 （一）股票种类：仍为人民币普通股； （二）股票简称：由"南华生物"变更为"*ST生物"； （三）股票代码：仍为"000504"； 1 1.南华生物医药股份有限公司（以下简称"公司"）股票将于2025年4 ...

Financial Performance - In 2024, the company's total profit, net profit, and net profit after deducting non-recurring gains and losses were all negative, with operating revenue falling below 300 million RMB, triggering delisting risk warnings[6]. - The company's operating revenue for 2024 was ¥134,447,796.85, a decrease of 1.71% compared to ¥136,790,924.97 in 2023[22]. - The net profit attributable to shareholders for 2024 was -¥19,846,018.35, an improvement of 29.56% from -¥28,172,625.54 in 2023[22]. - The net cash flow from operating activities decreased by 86.79% to ¥4,793,582.85 in 2024, down from ¥36,276,713.53 in 2023[22]. - The total assets at the end of 2024 were ¥608,169,817.97, a decline of 21.16% from ¥771,382,516.09 at the end of 2023[23]. - The net assets attributable to shareholders decreased by 7.72% to ¥237,095,180.02 at the end of 2024, compared to ¥256,941,198.37 at the end of 2023[23]. - The company reported a basic earnings per share of -¥0.06 for 2024, improving from -¥0.09 in 2023[22]. - The company reported a main business revenue of less than 300 million yuan, indicating insufficient scale to cover operating costs and ongoing losses[105]. Strategic Adjustments - The company plans not to distribute cash dividends, issue bonus shares, or convert reserves into share capital[7]. - The company has undergone a strategic adjustment in its major shareholder structure, with the largest shareholder holding 25.58% of the total shares after a transfer of shares[21]. - The company has established several subsidiaries, including Hunan Caixin Energy Conservation Technology Co., Ltd. and Nanhua Biyouhan (Hunan) Biotechnology Co., Ltd.[93]. - The company completed the acquisition of Hunan Caixin Energy Conservation and Environmental Protection Technology Co., Ltd. in July 2024, with full control over assets and management[171]. - The company has established a joint venture, Nanhua Biopharmaceutical (Hunan) Technology Co., Ltd., in September 2024, maintaining control over financial and operational teams[171]. Market and Industry Insights - The global stem cell manufacturing market is projected to grow from $15.08 billion in 2024 to $24.45 billion by 2029, indicating a strong growth potential in the industry[33]. - The Chinese stem cell market is expected to reach approximately ¥265 billion in 2024, with the collection, preparation, and storage segment nearing ¥160 billion[33]. - The company's energy-saving and environmental protection industry output value reached 9.8 trillion yuan in 2024, with expectations to grow to approximately 15 trillion yuan by 2030, indicating a rapid expansion of the market scale[34]. Research and Development - The company has established 10 innovation platforms, including provincial and national research centers, enhancing its competitive advantage in the biopharmaceutical industry[50]. - The company has over 90 patents and software copyrights, reflecting its commitment to research and development in both biopharmaceutical and energy-saving technologies[51]. - The company is developing a serum-free culture system for umbilical mesenchymal stem cells, which is expected to enhance safety and expand product offerings in pediatric disease treatment[68]. - The company is exploring exosome separation and purification processes, aiming to develop cell therapy products for neonatal acute respiratory distress syndrome[68]. - The company is enhancing its product pipeline with innovative cell therapy products, aiming to capture early opportunities in clinical research and applications[69]. Operational Efficiency - The company is implementing cost reduction and efficiency improvement measures to enhance revenue and profitability[105]. - The company has improved production efficiency and reduced costs through technological innovations in cell culture systems and automation[55]. - The company aims to reduce energy consumption for enterprises through comprehensive energy-saving project investments, focusing on urban lighting system retrofitting and energy efficiency in industrial and commercial buildings[37]. - The company has committed to improving production efficiency and operational effectiveness through resource optimization and internal management[96]. Governance and Compliance - The company maintains independent operations and governance, ensuring no interference from controlling shareholders in decision-making processes[116]. - The board of directors consists of 7 members, including 3 independent directors, adhering to governance regulations[117]. - The company ensures timely and accurate information disclosure, with designated platforms for investor communication[120]. - The company has established a complete legal governance structure and internal management system to ensure independent operation[187]. - The company is committed to maintaining transparency and compliance with stock exchange regulations[157]. Financial Management - The company has reduced interest-bearing liabilities, resulting in a significant decrease in financial expenses by 102.62%[67]. - The company reported a net cash flow from operating activities of CNY 4,793,582.85, a significant decrease of 86.79% compared to the previous year[73]. - The company has committed to minimizing related party transactions and ensuring fair pricing in unavoidable transactions[191]. - The company has maintained a continuous audit service with Tianjian Accounting Firm for 11 years, with an audit fee of 613,500 CNY[198]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 1.32 billion yuan[131]. - The company plans to invest 100 million yuan in new technology to improve production efficiency over the next two years[131]. - The company aims to enhance its core technology and focus on R&D in stem cells, immune cells, beauty products, and energy conservation by 2025[95]. - The company plans to enhance its beauty business by increasing investment and technological development to combine biotechnology with beauty products, aiming for revenue growth[97].

Financial Performance - The company's revenue for Q1 2025 was ¥22,453,576.28, a decrease of 13.55% compared to ¥25,973,854.69 in the same period last year[5] - The net loss attributable to shareholders was ¥2,218,632.26, an improvement of 19.92% from a loss of ¥2,770,653.53 in the previous year[5] - Net profit for the current period is -¥6,522,060.18, compared to -¥2,846,531.87 in the previous period, indicating a significant increase in losses[19] - Total operating revenue for the current period is ¥22,453,576.28, a decrease of 13.7% from ¥25,973,854.69 in the previous period[18] - Total operating costs increased to ¥30,056,727.81, up 0.3% from ¥29,981,563.79 in the previous period[18] - The total comprehensive income for the current period is -¥6,522,060.18, compared to -¥2,846,531.87 in the previous period[19] Cash Flow and Liquidity - The net cash flow from operating activities improved by 45.15%, reaching -¥825,292.27 compared to -¥1,504,744.35 in the prior year[5] - Operating cash flow for the current period is -¥825,292.27, an improvement from -¥1,504,744.35 in the previous period[21] - Cash and cash equivalents at the end of the period decreased to ¥141,375,896.11 from ¥212,597,686.65 in the previous period[22] - The company's cash and cash equivalents decreased by 31.81% to ¥141,405,896.11, primarily due to investments in bank wealth management products[8] - Investment activities generated a net cash outflow of -¥63,643,586.86, compared to -¥118,821,316.99 in the previous period, indicating reduced cash outflow[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥601,914,862.34, a decrease of 1.03% from ¥608,169,817.97 at the end of the previous year[5] - Current assets decreased to CNY 389,870,377.50 from CNY 401,904,309.43, primarily due to a reduction in cash and cash equivalents[15] - The company's inventory decreased by 35.74% to ¥21,886,655.45, mainly due to reduced stock levels at subsidiaries[8] - Accounts receivable decreased from CNY 139,581,939.21 to CNY 124,633,751.11, a reduction of approximately 10.7%[15] - Total liabilities remained relatively stable, with a slight increase from CNY 326,171,710.73 to CNY 326,671,985.01[16] - The company's total equity decreased from CNY 281,998,107.24 to CNY 275,242,877.33, indicating a decline of about 2.7%[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,992[11] - The largest shareholder, Hunan Caixin Industrial Fund Management Co., Ltd., holds 29.74% of the shares, totaling 98,150,852 shares[11] Earnings Per Share - The company's basic and diluted earnings per share improved to -¥0.0067, a 20.24% increase from -¥0.0084 in the same period last year[5] - The basic and diluted earnings per share for the current period are both -¥0.0067, compared to -¥0.0084 in the previous period[19] Research and Development - The company reported a significant increase in research and development expenses to ¥2,816,476.66, up from ¥2,184,441.44 in the previous period[18] Audit Status - The company has not undergone an audit for the first quarter report[23]

| | 2025/4/28 | 星期一 | 新股发行及今日交易提示 | | | --- | --- | --- | --- | --- | | 2025/4/28 | 新股发行 | | | | | 证券代码 | | 证券简称 | 发行价格 | | | 920068 | | 天工股份 | 3.94 | | | 301636 | | 泽润新能 | 33.06 | | | 2025/4/28 | | 内地市场权益提示 | | | | 类别 | 证券代码 | 证券简称 | 权益日期 | 最新公告链接 | | | | | 要约申报期1：2025年4月8日至2025年5月7日 | https://www.cninfo.com.cn/new/disclosure/detail?stockCode=600777&announcementId=122319 2301&orgId=gssh0600777&announcementTime=2025 -04-22 | | 要约收购 | 600777 | ST新潮 | 要约申报期2：2025年4月23日至2025年5月22日 | https://www.cninfo.com.cn/n ...

邮箱：xuyl@csco.com.cn 公司具备证券投资咨询业务资格 证券研究报告 医药生物 G 国产创新药闪耀 ASCO [Table_ReportType] 医药生物行业周报（4 月第 4 周） [Table_S 行业ummary 观点：] 请务必阅读文后重要声明及免责条款 [Table_ReportDate] 2025 年 04 月 28 日 [Table_Author] 分析师：王俐媛 执业证书号：S1030524080001 电话：0755-83199599 邮箱：wangly1@csco.com.cn 研究助理：徐伊琳 电话：0755-23602217 [Table_Industry] [Table_BaseData] 1) 周度回顾。上周（4 月 21 日-4 月 25 日）医药生物收 涨 1.16%，跑赢 wind 全 A（1.15%）和沪深 300（0.38%）。 从板块来看，医疗研发外包（6.34%）和原料药（4.72%） 部分个股一季报表现亮眼，涨幅居前，血液制品（- 3.26%）和疫苗（-6.38%）延续上周跌势。从个股来看， 永安药业（31.4%）、舒泰神（28.4%）和尔康制药（2 ...